Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Urogen Pharma Ltd
(NQ:
URGN
)
13.73
-0.24 (-1.72%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Urogen Pharma Ltd
< Previous
1
2
3
4
5
6
7
Next >
UroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102
March 14, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Earnings Scheduled For March 14, 2024
March 14, 2024
Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter.
Via
Benzinga
Earnings Outlook For UroGen Pharma
March 13, 2024
Via
Benzinga
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 08, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results on Thursday, March 14, 2024
March 04, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma to Present at TD Cowen 44th Annual Health Care Conference
February 26, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma to Participate at Upcoming Investor Conferences
February 01, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Recap: UroGen Pharma Q3 Earnings
November 14, 2023
Via
Benzinga
Preview: UroGen Pharma's Earnings
November 13, 2023
Via
Benzinga
The Latest Analyst Ratings for UroGen Pharma
October 04, 2023
Via
Benzinga
UroGen Initiates Submission of a Rolling NDA to the FDA for UGN-102
January 24, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Secures Exclusive License from medac GmbH to Develop a Next-Generation Novel Mitomycin-Based Formulation for Urothelial Cancers
January 17, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma to Participate in the B. Riley Healthcare Conference
January 11, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 08, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Where UroGen Pharma Stands With Analysts
July 31, 2023
Via
Benzinga
Two Months After Hamas Attacks, Gaza Conflict Intensifies As Ceasefire Efforts Falter
December 07, 2023
Two months after Hamas attacks, US President Biden, UNSC & King of Jordan call for ceasefire. Israeli stocks rise, US envoy to UN against ceasefire. Investigations into civilian casualties & use of...
Via
Benzinga
UroGen Pharma Reports Third Quarter 2023 Financial Results
November 14, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen will Present Scientific Advances in Bladder Cancer at the Annual Meeting of the Society of Urologic Oncology
November 13, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023
November 07, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Cathie Wood's ARK Israel Innovative Tech ETF Braces For Impact Amid Regional Warfare: 10 Stocks To Watch
October 09, 2023
Discover how Cathie Wood's ARK Israel Innovative Tech ETF responds to the Israel-Hamas conflict. Explore its portfolio performance and top Israeli stocks to watch amidst geopolitical turmoil.
Via
Benzinga
Topics
ETFs
Following Pre-NDA Meeting with the FDA, UroGen Announces Rolling NDA Submission for UGN-102 to Begin January 2024
October 03, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors
September 11, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 08, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma to Present at Upcoming Investor Conferences
August 31, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma Reports Record JELMYTO Quarterly Sales and Recent Corporate Developments
August 10, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
The Journal of Urology Publishes Peer-Reviewed Article Highlighting UGN-102 Data in Non-Surgical Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
August 08, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Why NICE Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
August 17, 2023
Gainers PhenomeX Inc. (NASDAQ: CELL) shares surged 138.3% to $0.9532. Bruker Corporation and PhenomeX reported a $108 million definitive agreement for Bruker to acquire PhenomeX in an all-cash...
Via
Benzinga
UroGen Pharma to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023
August 02, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Earnings Scheduled For August 10, 2023
August 10, 2023
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million.
Via
Benzinga
$10 Trillion Added In Market Cap; 2023’s Best And Worst Through July
August 01, 2023
The US stock market has now seen an increase in market cap of roughly $10 trillion from its bear market low last October through the end of July 2023.
Via
Talk Markets
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.